Recombinant DNA technology — the deliberate combination of genetic material from different sources into a single organism — carries categories of risk distinct from its technical function, and these risks are addressed through institutional governance rather than through the biology itself. The field distinguishes biosafety risks (accidental creation or release of a hazardous construct, and occupational exposure of researchers), ethical questions raised by the capacity to alter a genome (therapeutic correction versus enhancement, and the unknown long-term consequences of heritable modification), and privacy risks arising from the capacity to read a genome (genetic fingerprinting as an identifier, and genetic discrimination in insurance and employment). This topic sits at the intersection of molecular biology, bioethics, and science policy, and it establishes the principle that technical capability in genetic engineering is bounded by regulatory guidelines and normative judgment, not only by feasibility.
Recombinant DNA technology — the deliberate combination of genetic material from different sources into a single organism — carries categories of risk distinct from its technical function, and these …